915100-75-3Relevant academic research and scientific papers
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit
Backes, Bradley J.,Longenecker, Kenton,Hamilton, Gregory L.,Stewart, Kent,Lai, Chunqiu,Kopecka, Hana,von Geldern, Thomas W.,Madar, David J.,Pei, Zhonghua,Lubben, Thomas H.,Zinker, Bradley A.,Tian, Zhenping,Ballaron, Stephen J.,Stashko, Michael A.,Mika, Amanda K.,Beno, David W.A.,Kempf-Grote, Anita J.,Black-Schaefer, Candace,Sham, Hing L.,Trevillyan, James M.
, p. 2005 - 2012 (2008/02/01)
A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was replaced with a pyrrolidine to enable paralle
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
-
Page/Page column 24, (2010/11/24)
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
